Eribulin for advanced HER2-negative breast cancer after ADC treatment
Part of Cancer clinical trials.
This trial is testing a drug called eribulin (given alone or with other drugs) for people with advanced HER2-negative breast cancer that has already been treated with an ADC (antibody-drug conjugate). The goal is to see if this new treatment can help control the cancer and potentially shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- Your breast cancer must be locally advanced or metastatic (spread) and not operable
- Your cancer must be HER2-negative (a specific protein marker)
- You must have already been treated with an ADC (antibody-drug conjugate) for advanced disease
- You must have had no more than 2 previous chemotherapy treatments (including the ADC) for advanced disease
- You need to be physically able to get around (ECOG 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
This trial tests a combination of three drugs for advanced breast cancer that is both hormone-receptor-positive and HER2-positive, and has stopped responding to a newer targeted therapy called T-DXd. The goal is to see if this new combo can shrink tumors or slow their growth.
This trial is for people with advanced triple-negative breast cancer that has a specific gene change (PIK3CA). It tests a combination of two drugs (inavolisib and eribulin) to see if they can help shrink or control the cancer. If you've had prior treatment but it didn't work well enough, you may be a candidate.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Hear when a new Treatment Efficacy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.